The anterior pituitary-derived hormone prolactin (PRL) signals through the PRL receptor (PRLR) and is important for female reproductive function in mammals. In contrast to the extensive studies of PRLR expression and regulation in human and mouse ovary and uterus, the mechanisms controlling the regulation of PRLR isoform expression in the fallopian tube are poorly understood. Because dynamic interaction of hormonal signaling in gonadal tissue and the pituitary or in gonadal tissues themselves in mammals suggests endocrine or paracrine regulation of PRLR expression, we questioned whether differential regulation of PRLR isoforms by PRL ovarian-derived estrogen (E 2 ) and progesterone (P 4 ) exists in the fallopian tube and pituitary of prepubertal female mice. Western blot analysis showed distinct molecular separation of PRLR isoforms in mouse and human fallopian tubes, and cellular localization was found in mouse and human tubal epithelia but not in mouse tubal smooth muscle cells. These data support the concept of an isoform-and cell type-specific expression of PRLR in human and mouse fallopian tubes. Moreover, expression of the long form of PRLR decreased after PRL treatment and increased after blockage of endogenous PRL secretion by bromocriptine (an inhibitor of PRL secretion) in a time-dependent manner in mouse fallopian tube.
INTRODUCTION
Prolactin (PRL), which is synthesized and secreted by the anterior pituitary gland (primarily by lactotropes [1] ), participates in the regulation of female reproductive function in humans and rodents [2, 3] . The diverse biological actions of PRL are mediated through its cognate receptor, the transmembrane PRL receptor (PRLR), which is a member of the cytokine receptor superfamily that initiates signal transduction pathways and results in a series of coordinated physiological events in target endocrine tissues [4, 5] . Reported effects of PRL provide evidence for the importance of this hormone and PRLR on female fertility. For instance, hyperprolactinemia, a pathological condition, has been linked to a reduction of fertility due to disturbances in ovarian function in women [6] and inhibition of embryo implantation in mice [7] . Moreover, treatment with bromocriptine (an inhibitor of PRL secretion [8] ) can reverse infertility induced by prolactinomas (lactotroph adenomas) in young women [9] . Although it has become clear that elevation of circulating PRL suppresses fertility in mice [10] , targeted disruption of PRLR in female mice results in reduced fertility, uteri refractory to implantation [11, 12] , and increased circulating PRL level [12, 13] , highlighting that loss of function in PRL and PRLR signaling is the primary reason for the reproductive disorders seen in these animals.
Prolactin binding to the PRLR leads to rapid activation of receptor-associated signal transduction pathways [4, 5] . In humans, PRLR can also be activated in a PRL-independent fashion [14] . Multiple PRLR isoforms generated by alternative exon splicing of the PRLR gene have been identified in mammals [1, 2, 4] . The different isoforms in mice (long and short forms) and humans (long, intermediate, and short forms) have identical extracellular ligand-binding and transmembrane domains but varying intracellular domains [2] , suggesting that the maintenance of cellular responsiveness to PRL signals may differ between mice and humans. Given the critical role of the PRL and PRLR system in the physiological regulation of female reproduction, the relationship between reproductive tissues and regulation of PRLR expression is a fundamental issue in reproductive biology [15] . There is ample evidence that mouse and human ovaries [16] [17] [18] , mouse oocytes and embryos [19, 20] , and uterus [21] express PRLR. The coordinated temporal pattern of PRLR expression in the nonpregnant [22] [23] [24] [25] and pregnant [26] human uterus suggests that PRL may be involved in the establishment and maintenance of pregnancy. Furthermore, several comprehensive studies using rat models have demonstrated the presence of ovarian PRLR, reflecting circulating PRL and ovarian steroid hormone levels at different phases of the reproductive cycle [27] and PRL-induced upregulation of PRLR expression in the corpus luteum during pregnancy [28] . Although experiments have demonstrated the presence of PRL-binding sites in the fallopian tube [4] , there are no reports, to our knowledge, establishing the cell type-specific localization of PRLR and the presence of distinct PRLR isoforms in the mouse and human fallopian tubes. Although regulatory mechanisms operating PRLR changes are well known [2, 4, 5] , information regarding the intricate relationships between PRL and ovarian steroid hormone regulation of PRLR expression in the fallopian tube has not been elucidated in any species, as far as we know. Furthermore, ovarian steroid hormones estrogen (E 2 ) and progesterone (P 4 ) exert positive and negative regulatory effects on the synthesis and release of pituitary hormones, including PRL, to influence reproductive functions in mammals [2] [3] [4] [5] 29] . Therefore, we present a series of experiments that examine the effects of PRL and ovarian steroid hormone regulation on PRLR expression in the fallopian tube and the pituitary in mice. The effect of individual treatments on changes in circulating steroid hormones and PRL concentrations was also evaluated.
MATERIALS AND METHODS

Antibodies, Hormones, and Reagents
The primary antibodies and their final dilutions used in these studies are given in Table 1 . Alkaline phosphatase-conjugated goat anti-mouse IgG (A-1682; Sigma) and alkaline phosphatase-conjugated goat anti-rabbit IgG (AC31RL; Tropix) were used as secondary antibodies in Western blot analysis. Texas Red anti-mouse IgG, Texas Red anti-rabbit IgG, biotinylated anti-rabbit IgG, and fluorescein streptavidin were obtained from Vector Laboratories Inc. for immunofluorescence assay. 17b-Estradiol (E 2 ), 2-methoxyestradiol (2-ME), P 4 , PRL (luteotropic hormone from sheep pituitary glands), and 2-bromo-aergocryptine methanesulfonate salt (bromocriptine, a PRL secretion inhibitor) were purchased from Sigma. Other reagents were purchased from Sigma or Merck AG and were of the highest-purity grade available.
Animal Studies
All studies were performed with the approval of and in accord with guidelines established by the local ethics committee of Gothenburg University. Intact prepubertal female (21 days old) C57BL/6 mice obtained from Taconic M&B were used to avoid the effects of endogenous E 2 and of surgical procedures such as ovariectomy to remove the main source of endogenous E 2 production in adult mice. All animals were maintained in standard cages under 12L:12D with a 1-h dawn/sunset function at 21 6 28C with relative humidity between 45% and 55% and had ad libitum access to normal rodent chow and water.
Experimental Design and Tissue Preparation in Mice
Experiment 1: PRLR isoform expression analysis in mice. To ascertain the expression of PRLR isoforms in female mouse tissues, the fallopian tube, pituitary, and liver were collected from 21-days-old female mice (n ¼ 3) and were freed from fat or connective tissue immediately after the animals were killed. Tissues were frozen in liquid nitrogen for Western blot analysis.
Experiment 2: PRLR isoform expression responses to PRL or bromocriptine stimulation. To examine whether exogenous PRL or blockage of endogenous PRL secretion regulated PRLR isoform expression, 21-days-old female mice were s.c. treated daily with PRL (50 lg/animal/day) or bromocriptine (300 lg/animal/day) for 4 days (from 900 to 1000 h). Prolactin was dissolved in 0.9% saline, whereas bromocriptine was suspended in 100 ll of sesame oil (Sigma). Because dopaminergic stimulation via the dopamine D 2 receptor is instrumental in the control of PRL secretion in mammals [29] , we used bromocriptine, a dopamine agonist, to suppress the high intrinsic secretory activity of the pituitary lactotrophs in mice. The selected dose of PRL or bromocriptine and the treatment regimen have previously been used to demonstrate the immunoregulatory effects of PRL in mice in vivo [8, 30] . No time-dependent effect of vehicle (saline or sesame oil) was observed (data not shown). Mice were killed after treatment from Day 1 up to Day 5, and their fallopian tubes and pituitaries were removed and processed for the preparation of a protein extract as described herein or were fixed for histology as described previously [31] [32] [33] [34] .
Experiment 3: PRLR isoform expression responses to 17b-estradiol, 2-ME, or P 4 treatment. To examine whether exogenous E 2 and P 4 regulated PRLR isoform expression, 21-day-old female mice were given one s.c. injection of 17b-estradiol (E 2 , 0.3 mg/kg), 2-ME (1 mg/kg), or P 4 (4 mg/kg). After 1, 6, 24, and 48 h of treatment, animals were killed, and their fallopian tubes and pituitaries were collected. All compounds were suspended in 100 ll of sesame oil (Sigma). A pilot study was conducted to determine the appropriate doses of E 2 and P 4 . Immature female mice received a single injection of E 2 (0.05, 0.3, or 2 mg/kg) or P 4 (1, 4, or 40 mg/kg) based on previously published articles [34] [35] [36] to establish an effective concentration for E 2 and P 4 in the fallopian tube in vivo. Mouse uterine weight was monitored to determine that the substances and doses administered were sufficient to affect fallopian tube tissue. The E 2 and P 4 treatment paradigm is based on previous studies [31] [32] [33] [34] of the regulation of E 2 receptors (ERs) and P 2 receptors (PRs) in the fallopian tube as it relates to tubal function. The dose of 2-ME, an endogenous mammalian metabolite of E 2 , used in the present study has been previously demonstrated to have an effect in E 2 -target rat tissues in vivo [37] . No time-dependent effect of vehicle (sesame oil) was observed (data not shown). 
PRLR ISOFORM EXPRESSION IS REGULATED BY MULTIPLE HORMONES
Human Studies
An isthmus portion of the fallopian tubes was obtained from 11 fertile women, aged 28-42 yr, undergoing tubal ligations at Sahlgrenska University Hospital. Informed consent from the patients and approval by the institutional committee on the use of human subjects in research at Gothenburg University were obtained before collection of tissue samples for this study. All women had regular menstrual cycles (cycle length, 25-32 days), which were determined on the basis of menstrual history, and had a clinical examination before surgery. Endocrine parameters in control subjects were within the normal range. No woman had used hormonal medication within 3 mo of surgery. Immediately after collection, tissue was divided. One part of the tissue was fixed with 10% neutral buffered formalin, embedded in paraffin, sectioned, and mounted; the remainder was immediately placed into cold saline solution on ice in the operating room. All of the tissues were immediately brought to the laboratory and, unless indicated otherwise, were frozen at À708C for later analysis. Biopsy specimens were classified according to the stated last menstrual period and were verified by appropriate serum levels of steroid hormones in blood samples collected from each patient just before operation. The tissue samples were classified as follicular phase (group I, n ¼ 4), periovulatory phase (group II, n ¼ 4), or luteal phase (group III, n ¼ 3) according to a previous study [38] .
Western Blot Analysis
Whole-tissue extracts for protein preparations were essentially performed as described previously [32, 34] . Ten millimolar iodoacetamide was included in each buffer used for protein preparations to prevent nonspecific disulfide linkage. One micromolar sodium orthovanadate as a phosphatase inhibitor was also added to the buffer for protein preparation. The protein content was determined using the bicinchoninic acid protein assay (Pierce). Western blot analyses were performed using standard procedures as described [34] . For each time point or treatment, equivalent amounts of protein from at least three individual fallopian tube extracts were pooled. Thirty micrograms of protein was directly electrophoresed on 4%-12% one-dimensional Bis-Tris gels (Novex). Blots generated with these extracts were probed using different primary antibodies. The immunosignal-CDP-Star substrate for alkaline phosphatase system (Tropix) was used to visualize protein bands. To reprobe the blot with another antibody, the blot was rehydrated in methanol, rinsed, and incubated with stripping buffer (65 mM Tris-HCl, 2% SDS, 100 mM bmercaptoethanol, pH 6.8) at 508C for 30 min. Immunoblotted signals were visualized using an LAS 1000 cooled charge-coupled device camera (Fujifilm) and ECL film (Amersham International). The amount of protein loaded was quantitated by densitometry using Image Gauge software (Fujifilm). Correct loading was evaluated by staining the gels with Coomassie blue. Signal intensities of the PRLR proteins were normalized to the gels stained with Coomassie blue as ratios to produce arbitrary densitometric units (ADUs) of relative abundance. To standardize the assay for measurement of PRLR proteins, we examined different starting protein concentrations for each sample. This study demonstrated the linearity and validity of ADUs for all immunoreactive bands in Western blot analysis [34] . All steps were performed at room temperature unless otherwise stated.
Immunofluorescence Staining and Confocal Laser Microscopy
For immunofluorescence studies, fallopian tube tissues were processed as described [31, 33] . After deparaffinization and rehydration, antigen retrieval was completed with 10 mM sodium citrate buffer (pH 6, 10 min in a 700-W microwave). The effect of the pH of the antigen retrieval buffer on staining quality was tested and suggested that optimal staining for PRLR occurred using citrate buffer at pH 6 (data not shown). Nonspecific binding was removed by incubation with PBS containing 1% BSA/5% normal goat serum for 1 h at room temperature. After incubation with primary antibody in PBS supplemented with Triton X-100 in a moist chamber overnight at 48C, sections were washed three times for 10 min in PBS and incubated for 60 min at room temperature with Cy3-conjugated anti-mouse secondary antibody. Sections were then washed for 10 min in PBS. The nuclei were fluorescently stained with 4,6-diamidino-2-phenylidone (DAPI, 1 mM in PBS). Sections were viewed on an Axiovert 200 confocal microscope (Carl Zeiss) equipped with a laser-scanning confocal imaging LSM 510 META system (Carl Zeiss) and photomicrographed. All settings, including laser power gain, amplifier gain, and amplifier offset, were set using a look-up table to provide an optimal intensity. Background settings were adjusted by examination of negative control specimens under identical instrument settings. The following two types of negative controls were performed: 1) the primary antibody was omitted or 2) IgG from normal mouse serum was used instead of the primary antibody at a corresponding protein concentration. Tissues from a minimum of five animals and eleven patients were evaluated to ensure the reproducibility of the results. The immunohistochemical findings presented are representative of those observed in random sections from multiple animals. Because immunofluorescence studies are not quantitative unless the signals are rendered virtually on or off by the experimental intervention, we did not attempt to assess differences using this technique; instead, we relied on Western blot analysis for quantification.
Assessment of Circulating Hormones
Trunk blood was collected following cardiac puncture. Serum was collected after centrifugation (14 000 rpm, 48C, 10 min) and stored at À708C until further processing.
Estradiol (E 2 ) and P 4 . Serum E 2 and P 4 measurements were performed within 2 wk of sample collection. Concentrations were measured by RIA according to a protocol provided by the manufacturer (PerkinElmer Life and Analytical Sciences) as described previously [31, 32, 34] . The sensitivity of the assay was typically better than 50 pmol/L for E 2 and 800 pmol/L for P 4 , and the intraassay coefficient of variation was 3.8%-10% for E 2 and 3.3%-7.3% for P 4 .
Prolactin. The serum PRL concentrations were determined in duplicate using a commercial enzyme immunoassay kit specific for rat PRL (Spi-Bio). All samples had PRL concentrations within the range of the standard curve. The intraassay and interassay coefficients of variation were 10.6% and 14.8%, respectively.
Data Presentation and Statistical Analysis
Each experiment was repeated at least twice and usually three times. The protein data herein were generated in three separate experiments. Data are presented as mean 6 SEM. Multiple comparisons between data were performed using one-way ANOVA, with correction of P values using the Bonferroni multiple-range tests in the Analyse-It program (Analyse-It Software, Ltd.). P , 0.05 was set as the limit of statistical significance.
RESULTS
Expression of PRLR Protein Isoforms in Selected Mouse Tissues and Human Fallopian Tube
Previous studies identified different PRLR transcripts in various mouse tissues, including ovary [16, 18] , oocytes [19] , embryos [19] , and liver [16, 39] . To determine whether PRLR exhibits a differential tissue distribution and whether diversity of PRLR protein isoforms exists, Western blot analysis was performed using a monoclonal PRLR antibody (U5) that has been well characterized previously [40] . As expected, our analysis revealed that two molecular weight bands corresponding to the long form (;97 kDa) and short form (;45 kDa) of PRLR were detected in mouse fallopian tube, pituitary, and liver (Fig. 1) . However, there were appreciable differences in protein expression levels between the different PRLR isoforms and tissues. Expression of the long form was higher in the fallopian tube than in the pituitary and liver, while expression of the short form was higher in the pituitary and liver than in the fallopian tube. Furthermore, the ;45-kDa short form of the receptor was the predominant isoform expressed in the liver [41] , indicating that the expression level of each PRLR isoform is tissue specific. To determine whether any diversity in PRLR isoform expression exists in human fallopian tube compared with mouse fallopian tube, Western blot analysis was performed using total protein extracted from fallopian tubes from women with normal reproductive cycles. As already described, groups I, II, and III represent the follicular phase, periovulatory phase, and luteal phase, respectively. Immunoreactive PRLR bands were detected in all samples used in the present study. Three molecular weight bands that corresponded to the long form (;97 kDa), intermediate form (64-97 kDa), and short form (51-64 kDa) of human PRLR were evident (Fig. 1B) . Based on PRLR expression in the multiple cell types of human fallopian tube by immunofluorescence study (Fig. 2,  G and H) , we did not quantitate and normalize the changes in 750 PRLR protein isoforms to the gels stained with Coomassie blue, because homogenization of the entire fallopian tube included all of these different cell types and it would mask the changes in cell type-specific regulation of PRLR isoform expression. Expression of the signal intensity ratio for PRLR isoforms to pan-cytokeratin (a marker for epithelial cells) or to a-smooth muscle actin (a marker for muscle cells) showed a tendency to a cycle-related fluctuation in the long and intermediate forms of PRLR when normalized to the epithelial cell marker.
Cell-Specific Localization of PRLR in Selected Mouse Tissues and Human Fallopian Tube
Expression of PRLR was localized in mouse fallopian tube (Fig. 2, A-D) and pituitary (Fig. 2, E and F) by immunofluorescence and confocal laser microscopy. In accord with different anatomical and physiological requirements, the various tubal regions of rodent fallopian tube can be identified by specific morphological characteristics [31, 33] . Regardless of whether mice were stimulated by PRL, PRLR expression was principally localized in the cell membrane and cytoplasm of epithelial cells throughout the fallopian tube segments (Fig.  2, A-C) . The immunostaining intensity of PRLR was much greater in the apical cell membrane than in the cytoplasm of epithelial cells in the infundibulum portion ( Fig. 2A) . No staining was observed in the muscle cells in the tubal regions examined (Fig. 2, A-C) . These results have been validated using perioxidase labeling and optical microscope analysis. In addition, the similar intracellular localization pattern of PRLR was also seen in prepubertal rat fallopian tube using the same antibody (data not shown). Immunostaining for PRLR was also found in the pituitary cells (Fig. 2E) . Membrane staining was discerned only in a few cells, consistent with previous findings in the rat anterior pituitary [42] . Incubating sections with nonimmune IgG from the same tissue in fallopian tube (Fig.  2D) or pituitary (Fig. 2F) did not produce any specific immunoreactivity. Next, we documented the cellular localization of PRLR expression in human fallopian tube (Fig. 2, G  and I ). Different patterns of cellular immunostaining were found in human fallopian tube vs. in mouse fallopian tube (Fig.  2, A-C) . Prolactin receptor immunostaining was detected in epithelial, stromal, and muscle cells (Fig. 2, G and H) . This pattern of localization was consistently observed in the sections of all the fallopian tubes analyzed. Immunostaining for PRLR was absent in the same tubal section when incubated with nonimmune IgG (Fig. 2I) . These results indicate the differences FIG. 1 . Expression of PRLR isoforms and cell type-specific marker proteins in female mouse tissues (A) and human fallopian tube (B). Protein extracts from total lysates (30 lg/lane, n ¼ 3) were analyzed by Western blot using antibodies for PRLR, pan-cytokeratin, a-smooth muscle (SM) actin, and ACTB as described in Materials and Methods. Arrows indicate the presence of different PRLR isoforms. The apparent molecular weight of the protein is indicated on the left. Open triangles represent the nonspecific band. Groups I, II, and III represent the follicular phase, periovulatory phase, and luteal phase, respectively. Quantification of the level of PRLR isoform expression is shown in the bar graph. The amount of protein loaded was quantitated by staining the gels with Coomassie blue. Relative levels of PRLR isoform proteins were expressed as a ratio of PRLR densitometric value to whole protein in Coomassie blue staining in mouse tissues, while relative levels of PRLR isoform proteins in human fallopian tube were expressed as a ratio of PRLR densitometric value to the pan-cytokeratin or a-SM actin densitometric value.
in cell type and isoform expression of PRLR between human and mouse fallopian tube.
Regulation of PRLR Protein Isoforms by PRL or Bromocriptine in Mouse Fallopian Tube and Pituitary
Time course experiments shown in Figure 3 illustrate PRLR isoform expression in response to PRL (Fig. 3, A and B) and bromocriptine (Fig. 3, D and E) treatment in the fallopian tube (Fig. 3, A and D) and pituitary (Fig. 3, B and E) . Exposure of mice to PRL had no effect on PRLR isoform expression on Day 1 and Day 2 but significantly decreased the long form of PRLR expression from Day 3 up to Day 5 in the fallopian tube (Fig.  3A) . In contrast to the fallopian tube, the long form of PRLR was significantly elevated in the pituitary following PRL treatment from Day 1 up to Day 5 (Fig. 3B) . However, there was no effect of PRL on tubal ESR1 (ER a), ESR2 (ER b), and PR protein expression (Fig. 3A) or circulating E 2 and P 4 levels (Fig. 3C) . These findings demonstrated a direct PRL effect, independent of its influence on steroid hormone synthesis and ER/PR diverse signaling pathways in vivo. Conversely, inhibition of endogenous PRL secretion by bromocriptine did not alter PRLR isoform expression from Day 1 up to Day 3 but significantly increased expression of the long form from Day 4 and Day 5 in the fallopian tube (Fig. 3D) . In contrast, the long form of PRLR was suppressed following bromocriptine treatment in the pituitary at Day 1 only (Fig. 3E) . Neither tubal ESR1, ESR2, or PR protein expression (Fig. 3D) nor circulating P 4 levels (Fig.   3F ) were affected by bromocriptine treatment, but a decrease in circulating E 2 level was seen on Day 4 and Day 5 (Fig. 3F) . As anticipated, circulating PRL levels peaked on Day 2 and Day 3 after PRL treatment (Fig. 3C ) and fell dramatically on Day 1 after bromocriptine treatment (Fig. 3F) .
Regulation of PRLR Protein Isoforms by E 2 and P 4 in Mouse Fallopian Tube and Pituitary
Because cyclic changes of ovarian steroid hormones control homeostasis of the fallopian tubal epithelium [43] , we wanted to know whether the expression of PRLR isoforms in the fallopian tube and pituitary could be regulated acutely by E 2 , 2-ME, or P 4 . Time course experiments (1/6 and 24/48 h represent early and late steroid hormone responses, respectively) illustrate PRLR isoform expression in response to E 2 (0.3 mg/kg) and 2-ME (1 mg/kg) (Fig. 4) , as well as P 4 (4 mg/kg) (Fig. 5) , stimulation in the fallopian tube and pituitary. At 1, 6, and 24 h, tubal PRLR isoform expression was not affected by E 2 treatment. However, the expression of PRLR was significantly decreased in the fallopian tubes from 48-h E 2 -treated animals (Fig. 4A) . A similar inhibitory effect on PRLR expression was seen in the fallopian tubes from 24-h and 48-h P 4 -treated animals (Fig. 5A) . Treatment with E 2 suppressed the short form of PRLR expression, whereas P 4 regulated the long form of PRLR expression in the fallopian tube (as did PRL). In addition, as shown in Figure 4C , mice treated with E 2 responded similarly to those treated with P 4 (Fig. 5C)   FIG. 2 . Localization of PRLR protein in the mouse fallopian tube and pituitary and in the human fallopian tube. Mouse fallopian tube (A-D) and pituitary (E and F) and human fallopian tube (G from group I and H and I from group II) sections were immunolabeled for PRLR and visualized with the appropriate wavelength for PRLR (red) and DAPI (blue) as described in Materials and Methods. In mice, confocal microscopy revealed that strong PRLR immunoreactivity was selectively restricted to tubal epithelial cells (A-C) and some pituitary cells (E). Positive staining was not observed when irrelevant mouse IgG was substituted for the primary antibody in adjacent tubal (D) and pituitary (F) sections. Sections were subsequently counterstained with DAPI to visualize cell nuclei (A-1 to F-1, lower panels). Enhanced magnifications of merged exposure are shown at the right corner of A to F. The same results were obtained in replicate experiments using tissues from different mice (n ¼ 5). G and H) In humans, confocal microscopy revealed that strong PRLR immunoreactivity was selectively restricted to tubal epithelial and stromal cells. I) Positive staining was not observed when irrelevant mouse IgG was substituted for the primary antibody in an adjacent tubal section. Sections were subsequently counterstained with DAPI to visualize cell nuclei (G-1 to I-1, lower panels). Enhanced magnifications of merged exposure are shown at the right corner of G to I. epi, epithelial; m, muscle cells; str, stromal. . Total protein (30 lg/lane) was analyzed by Western blot using antibodies to PRLR, ESR1, ESR2, and PR(A/B) as described in Materials and Methods. Quantification of the level of PRLR isoform expression is shown in the bar graph. Relative levels of PRLR isoform proteins were expressed as the ratio of PRLR densitometric value to whole protein in the Coomassie blue staining. Tubal tissues were pooled (five organs per pool at each time point) for one experiment. The ADU values are the mean 6 SEM of three observations obtained from three independent experiments. Trunk blood was obtained by heart puncture. Serum E 2 , P 4 , and PRL concentrations (C and F) were measured (n ¼ 5). * P , 0.05, ** P , 0.01, and *** P , 0.001 vs. each control sample (Day 0), respectively.
(endogenous circulating PRL levels increased in a timedependent manner, although increases in mice treated with P 4 were not as great as those in mice treated with E 2 ), suggesting that endogenous PRL may also participate in the suppression of PRLR expression by steroid hormones in the fallopian tube. However, stimulation of mice with E 2 or P 4 had no effect on the regulation of PRLR isoforms in the pituitary (Figs. 4B and 5B). Furthermore, although a time-dependent stimulatory effect of 2-ME on proliferating cell nuclear antigen (PCNA) protein expression was observed in the fallopian tube, 48 h of 2-ME exposure did not alter PRLR isoform, ER (ESR1 and ESR2), progesterone receptor (PR), or b-actin (ACTB) protein expression (Fig. 4D) , nor did it alter circulating E 2 , P 4 , or PRL levels (Fig. 4E) , suggesting that the inhibitory effect of E 2 and P 4 seems to be mediated through the ER/PR system in the fallopian tube.
DISCUSSION
The present study provides new data concerning the tissuespecific expression of PRLR isoforms under the endocrine or paracrine influence of PRL and ovarian steroid hormones in mouse fallopian tube and pituitary in vivo. Subcutaneous administration of PRL evokes inhibition of PRLR expression in a time-dependent manner, whereas blockade of endogenous PRL secretion by bromocriptine induces a persistent stimulatory effect on PRLR expression in the fallopian tube. In contrast, PRL potently stimulates, while bromocriptine transiently inhibits, PRLR expression in the pituitary. Our data illustrate a complex mode of action of PRL on PRLR isoform expression, with inhibitory effects in reproductive tissue such as the fallopian tube but with direct stimulatory actions in the pituitary. Although the physiological levels of intratubular PRL are unknown at present, ovarian-derived PRL in follicular fluid [2, 3, 44] may be taken up by the fallopian tube and, consequently, act directly on epithelial cells to regulate and activate PRLR signaling in the fallopian tube. Therefore, the results obtained in the present investigation suggest involvement of endocrine or paracrine PRL signaling pathways in tissue-specific regulation of PRLR expression. Although PRL has been shown to increase ER expression in rat corpus luteum [28] , the present investigation demonstrates that treatment with PRL fails to alter ER and PR protein expression in the fallopian tube (or circulating E 2 and P 4 levels), supporting the assumption that PRL does not mediate ovarian steroid hormone responses that regulate PRLR expression in the fallopian tube .   FIG. 4 . Effects of E 2 and 2-ME on PRLR isoform expression and serum hormone concentrations in mice. Representative Western blot analysis of three experiments performed using different tubal samples (top). Protein was isolated from fallopian tube (A and D) and pituitary (B) of female mice treated with E 2 (A and B) or 2-ME (D). Total protein (30 lg/lane) was analyzed by Western blot using antibodies to PRLR, ESR1, ESR2, PR(A/B), PCNA, and ACTB as described in Materials and Methods. Quantification of the level of PRLR isoform expression is shown in the bar graph. Relative levels of PRLR isoform proteins were expressed as the ratio of the PRLR densitometric value to whole protein in the Coomassie blue staining. Tubal tissues were pooled (five organs per pool at each time point) for one experiment. The ADU values are the mean 6 SEM of three observations obtained from three independent experiments. Trunk blood was obtained by heart puncture. Serum E 2 , P 4 , and PRL concentrations (C and E) were measured (n ¼ 5). * P , 0.05 and *** P , 0.001 vs. each control animal (Day 0).
SHAO ET AL.
Epithelial cells of the mammalian fallopian tube are potential targets of ovarian steroid hormone (E 2 and P 4 ) actions [43] , which regulate the transcription of numerous target genes by binding to and activating the nuclear ER/PR [45] . In addition to PRL-induced PRLR regulation, results of our initial experiments suggest that changes in endogenous E 2 and P 4 levels in prepubertal female mice treated with gonadotropins affect circulating PRL level and expression of PRLR (data not shown), which led us to investigate the specific role of each steroid hormone in the regulation of PRLR isoform expression in the fallopian tube. Although manipulations of E 2 or P 4 display similar downregulation of PRLR protein level in mouse fallopian tube in vivo, the contribution of the long and short forms of PRLR seems to be diverse following E 2 or P 4 stimulation. It is known that PRL stimulation causes homodimerization or heterodimerization of the long and short forms of PRLR, which is essential for activation of the receptor [4, 5] . Differences between long and short forms of PRLR are reflected in differential transmembrane receptor processing. However, functional studies of each PRLR isoform are complicated by the fact that most PRL-target tissues express long forms and short forms of PRLR [2, 4] , as well as by the lack of highly selective pharmacological agents that inhibit or activate distinct PRLR isoforms. Although the physiological role of the resulting PRLR protein isoforms in PRL signaling is not fully understood, the functional properties of some PRLR isoforms have been characterized. For instance, only the long form of PRLR has been shown to induce phosphorylation of Stat5 and to confer transcriptional induction in the presence of PRL [5] , whereas it is not clear how PRL signal is transduced through the short form of PRLR. Recently, roles for the PRL-activated PRLR short form in mouse ovary have been proposed and described in ovarian impairment [13] . Hence, the reasons for the disparate effects of E 2 and P 4 on the regulation of PRLR isoform expression in the fallopian tube remain to be elucidated. Our studies [31, 33, 34] and those of several other groups [46] [47] [48] demonstrated that tubal epithelial cells express ER and PR in rodents and humans. In parallel to sequential ligand-induced activation of ER and PR [31, 33, 34] , exposure to E 2 or P 4 longer than 24 or 48 h alters PRLR expression in mouse fallopian tube. This matches the timing of E 2 and P 4 effects, suggesting that tubal PRLR expression is regulated by E 2 and P 4 via a paracrine mechanism requiring the presence of ER and PR in tubal epithelial cells. It seems that E 2 or P 4 , acting through nuclear receptors, initiates responses that include the induction of PRL (Figs. 4C and 5C ). Prolactin, in turn, interacts with its cognate PRLR to initiate a signaling cascade in the fallopian tube.
There seems to be regulatory cross-talk between PRL and ovarian steroid hormones in the regulation of PRLR expression in some physiological situations. Increases in physiological PRL levels are only observed in early pregnancy and during lactation [1] and are paralleled by changes in E 2 and P 4 levels in humans [2] . Because the circulating level of 2-ME, an endogenous estradiol metabolite, is also dramatically increased during pregnancy in humans [49] , it is feasible that 2-ME competes with E 2 for the regulation of PRLR expression. However, our experiments excluded a contribution of 2-ME in PRLR regulation in mouse fallopian tube. Overall, it is tempting to postulate that PRLR expression in human fallopian tube is likely regulated by E 2 /P 4 during the reproductive cycle or by a complex interplay of PRL and E 2 /P 4 during pregnancy, when circulating E 2 and PRL are markedly elevated. In mice, hyperprolactinemia results in uterine glandular hypertrophy [50] , and exogenous PRL is sufficient to increase levels of PCNA and phosphorylated histone H3 protein expression in mouse fallopian tube (data not shown), suggesting that PRLR may function as a proliferative regulator in the fallopian tube, particularly with respect to tubal epithelial cells in vivo. Our current state of knowledge suggests that tubal epithelial cells undergoing proliferation and differentiation are controlled primarily by ovarian steroid hormones [43] . Although we cannot definitively conclude that PRL-induced changes in cell proliferation are due to a particular PRLR isoform or due to variable expression of each, it may be worthwhile to consider that the physiological level of PRL may elicit a proliferative response in the epithelial cells through regulation of PRLR expression, even in the absence of ovarian steroid hormones in the fallopian tube. Therefore, focusing on the cellular Relative levels of PRLR isoform proteins were expressed as the ratio of the PRLR densitometric value to whole protein in the Coomassie blue staining. Tubal tissues were pooled (five organs per pool at each time point) for one experiment. The ADU values are the mean 6 SEM of three observations obtained from three independent experiments. Trunk blood was obtained by heart puncture. Serum samples were collected after clotting and centrifugation. Serum PRL concentrations (C) were measured (n ¼ 5). *** P , 0.001 vs. each control animal (Day 0). mechanisms of regulation of PRLR isoform expression in mouse fallopian tube may provide insight into the action of PRL contributing to human reproduction. For example, PRL directly stimulates transcellular active Ca 2þ transport and influences Ca 2þ absorption in the intestinal epithelial cells in female rats [51] . It has been shown that the functionally characterized membrane proximal box 1 and the COOHterminal region of PRLR are required for PRL-induced cellular Ca 2þ transport processes [52] . These findings could indicate that the possible role of PRLR is involved in the regulation of Ca 2þ -dependent ciliary beats for gamete and embryo transport in the fallopian tube, a hypothesis that has not been tested experimentally in the present study. With respect to the relevance of our findings to normal in vivo physiology, it is also important to consider the role of PRLR in disease such as hyperprolactinemia-induced reproductive dysfunction in women [6] . Deviations from well-controlled functions of tubal epithelial cells can cause infertility and states of disease. Because targeted disruption of PRLR in female mice with raised levels of PRL [12, 13] induces irregular estrous cycles and impaired fertilization [11, 12] , future studies will need to determine whether the absence of PRLR in mouse fallopian tube leads to epithelial cell dysfunction.
Ovarian steroid hormone feedback mechanisms have been proven to be important for regulation of reproductive function [2] [3] [4] [5] 29] . In vivo, E 2 and P 4 have been reported to positively regulate pituitary PRL secretion [53] . Although in vivo regulation of PRL synthesis and secretion is not fully understood, several previous investigations showed that rodent pituitaries express ER [54] [55] [56] and PR [57] [58] [59] . Nevertheless, determination of whether exogenous E 2 or P 4 directly regulates PRLR isoform expression in the pituitary is of great interest. Time-dependent increases in circulating PRL levels by E 2 or P 4 treatment are in agreement with a previous in vitro study [53] . Much to our surprise, although E 2 and P 4 suppress PRLR expression in the fallopian tube, neither regulated PRLR isoform expression in the pituitary. In addition to the variable expression of PRLR isoforms in the two tissues, these data suggest that tissue-specific actions of E 2 and P 4 could be contributory factors. Recent studies demonstrated that influences of E 2 on PRL secretion may be regulated indirectly through induction of hypothalamic PRLR, affecting feedback sensitivity of PRL at the hypothalamic level [60] rather than through direct pituitary ESR1 stimulation [61] . Our finding that ovarian steroid hormones do not regulate pituitary PRLR isoform expression supports the notion of indirect E 2 regulation of PRL secretion.
In summary, we made the novel observation that different protein isoforms of PRLR exist in mouse and human fallopian tubes. These isoforms are differentially expressed, and cell types are specifically localized in the fallopian tube. Furthermore, our experiments not only provide specific details concerning how dynamic changes in PRLR isoform expression are mediated by PRL and ovarian steroid hormones but also point to different mechanisms for coordinated regulation of PRLR expression in vivo. There are a number of important issues yet to be addressed with regard to the physiological significance of specific PRLR isoforms in the fallopian tube in vivo.
